F. Boudes Pol's most recent trade in Galectin Therapeutics Inc was a trade of 65,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 24, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | F. Boudes Pol | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | F. Pol Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 40,000 | 40,000 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 100,000 | 100,000 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 50,000 | 50,000 | - | - | Stock option (right to buy) |